*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
In the Wall Street Biobeat column of the September 1st issue of GEN, Robert Dellenbach wrote that significant changes in the global economy and in the venture capital community have dramatically impacted the life sciences industry. What's more, his article appeared even before last month's near Wall Street meltdown. What's a biotech company to do for money?
GEN held a roundtable discussion with several industry professionals to find out. We discovered that dealmaking with pharma firms was on a dramatic upswing, and not just due to a lack of VC funding. The panel answered questions such as: What's driving the recent spate of deals, especially all the M&A and partnering activities between pharmaceutical companies and biotech firms? What does a pharma firm look for in a biotech company before entering such deals? What does a biotech company need to do to get the attention of a large pharmaceutical company? Does it seem like deals, and not drug products themselves or specific technologies, are now the main driving force behind the bio industry's growth?
Anyone involved in the biotechnology industry will find this podcast extremely compelling and timely as the biopharmaceutical industry continues to search for new and creative avenues of financing!
Barbara Yanni is Chief Licensing Officer at Merck & Co.
David Colpman is Senior VP of Business Development at Shire Pharmaceuticals.
Joern-Peter Halle is Head of Early-Stage Licensing at Merck Serono, a division of Merck KGaA
Martina Molsbergen is VP of Business Development at Crucell.